Display Settings:

Format

Send to:

Choose Destination
J Ophthalmic Vis Res. 2012 Jan;7(1):39-44.

Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts.

Author information

  • 1Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.

Abstract

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine produced by macrophages and T-cells. It plays an important role both in inflammation and apoptosis. In the eye, TNF-α appears to have a role in the pathogenesis of inflammatory, edematous, neovascular and neurodegenerative disorders. Several TNF-blocking drugs have been developed and approved, and are in clinical use for inflammatory diseases such as rheumatoid arthritis, psoriasis and ankylosing spondylitis. TNF-α blockers are widely used in ophthalmology as an off-label alternative to "traditional" immunosuppressive and immune-modulatory treatments in noninfectious uveitis. Preliminary studies suggest a positive effect of intravenously administered TNF-α blockers, mainly infliximab, for treating refractory diabetic macular edema and neovascular age-related macular degeneration. Unfortunately, much of the current data raises considerable safety concerns for intravitreal use of TNF-α inhibitors, in particular, intraocular inflammatory responses have been reported after intravitreal injection of infliximab. Results of dose-finding studies and humanized antibody or antibody fragments (e.g. adalimumab) are anticipated in the coming years; these will shed light on potential benefits and risks of local and systemic TNF-α blockers used for treatment of diseases of the retina and choroid.

KEYWORDS:

Age-Related Macular Degeneration; Diabetic Macular Edema; TNF-α; Tumor Necrosis Factor; Uveitis, Retinal Vein Occlusion

PMID:
22737386
[PubMed]
PMCID:
PMC3381107
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk